Lorea Valcarcel-Jimenez
Overview
Explore the profile of Lorea Valcarcel-Jimenez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valcarcel-Jimenez L, Frezza C
Br J Cancer
. 2023 Sep;
129(10):1546-1557.
PMID: 37689804
Fumarate hydratase (FH) is an enzyme of the Tricarboxylic Acid (TCA) cycle whose mutations lead to hereditary and sporadic forms of cancer. Although more than twenty years have passed since...
2.
Rogerson C, Sciacovelli M, Maddalena L, Pouikli A, Segarra-Mondejar M, Valcarcel-Jimenez L, et al.
Cell Rep
. 2023 Jul;
42(7):112751.
PMID: 37405921
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a cancer syndrome caused by inactivating germline mutations in fumarate hydratase (FH) and subsequent accumulation of fumarate. Fumarate accumulation leads to profound...
3.
Valcarcel-Jimenez L, Rogerson C, Yong C, Schmidt C, Yang M, Cremades-Rodelgo M, et al.
Sci Adv
. 2022 Oct;
8(42):eabq8297.
PMID: 36269833
Fumarate hydratase (FH) is a mitochondrial enzyme that catalyzes the reversible hydration of fumarate to malate in the tricarboxylic acid (TCA) cycle. Germline mutations of lead to hereditary leiomyomatosis and...
4.
Monelli E, Villacampa P, Zabala-Letona A, Martinez-Romero A, Llena J, Beiroa D, et al.
Nat Metab
. 2022 Mar;
4(3):327-343.
PMID: 35288722
Reciprocal interactions between endothelial cells (ECs) and adipocytes are fundamental to maintain white adipose tissue (WAT) homeostasis, as illustrated by the activation of angiogenesis upon WAT expansion, a process that...
5.
Romani P, Valcarcel-Jimenez L, Frezza C, Dupont S
Nat Rev Mol Cell Biol
. 2020 Nov;
22(1):22-38.
PMID: 33188273
Mechanical forces shape cells and tissues during development and adult homeostasis. In addition, they also signal to cells via mechanotransduction pathways to control cell proliferation, differentiation and death. These processes...
6.
Hermanova I, Zuniga-Garcia P, Caro-Maldonado A, Fernandez-Ruiz S, Salvador F, Martin-Martin N, et al.
J Exp Med
. 2020 Mar;
217(6).
PMID: 32219437
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model...
7.
Valcarcel-Jimenez L, Macchia A, Crosas-Molist E, Schaub-Clerigue A, Camacho L, Martin-Martin N, et al.
Cancer Res
. 2019 Oct;
79(24):6153-6165.
PMID: 31594836
The PPARγ coactivator 1 alpha (PGC1α) is a prostate tumor suppressor that controls the balance between anabolism and catabolism. PGC1A downregulation in prostate cancer is causally associated with the development...
8.
Arreal L, Piva M, Fernandez S, Revandkar A, Schaub-Clerigue A, Villanueva J, et al.
Cell Death Differ
. 2019 Oct;
27(4):1186-1199.
PMID: 31570853
Oncogene addiction postulates that the survival and growth of certain tumor cells is dependent upon the activity of one oncogene, despite their multiple genetic and epigenetic abnormalities. This phenomenon provides...
9.
Valcarcel-Jimenez L, Macchia A, Martin-Martin N, Cortazar A, Schaub-Clerigue A, Pujana-Vaquerizo M, et al.
Cell Death Dis
. 2018 Oct;
9(10):1041.
PMID: 30310055
The dysregulation of gene expression is an enabling hallmark of cancer. Computational analysis of transcriptomics data from human cancer specimens, complemented with exhaustive clinical annotation, provides an opportunity to identify...
10.
Caro-Maldonado A, Camacho L, Zabala-Letona A, Torrano V, Fernandez-Ruiz S, Zamacola-Bascaran K, et al.
Oncotarget
. 2018 Feb;
9(2):1494-1504.
PMID: 29416709
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo...